Literature DB >> 20674368

New effective inhibitors of the Abelson kinase.

George A Kraus1, Vinayak Gupta, Marjan Mokhtarian, Samir Mehanovic, Marit Nilsen-Hamilton.   

Abstract

The effects of substituents on the aryl ring were studied by the preparation and testing of several PD173955 analogs. Inserting a single carbon atom into the C-N bond in the aniline subunit (PDC) reduced the kinase inhibition by a factor of 200. Despite its decreased affinity for Abl compared with PD173955, PDC exhibits a Ki very similar to that reported for Imatinib. Increased water solubility is also gained by replacing the thiomethyl group with an amino or glycyl moiety. For both PD173955 and PDC, the analogs with amino groups in place of the methylthio group are 10 times more inhibitory than the parent molecules. Two molecules were identified with Kis about three orders of magnitude lower than reported for Imatinib. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20674368      PMCID: PMC3891048          DOI: 10.1016/j.bmc.2010.07.021

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  14 in total

Review 1.  The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

Authors:  Michael Deininger; Elisabeth Buchdunger; Brian J Druker
Journal:  Blood       Date:  2004-12-23       Impact factor: 22.113

2.  NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

Authors:  Susan O'Brien; Ellin Berman; Hossein Borghaei; Daniel J Deangelo; Marcel P Devetten; Steven Devine; Harry P Erba; Jason Gotlib; Madan Jagasia; Joseph O Moore; Tariq Mughal; Javier Pinilla-Ibarz; Jerald P Radich; Neil P Shah Md; Paul J Shami; B Douglas Smith; David S Snyder; Martin S Tallman; Moshe Talpaz; Meir Wetzler
Journal:  J Natl Compr Canc Netw       Date:  2009-10       Impact factor: 11.908

3.  Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.

Authors:  M M Moasser; M Srethapakdi; K S Sachar; A J Kraker; N Rosen
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

4.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors:  T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal:  Science       Date:  2000-09-15       Impact factor: 47.728

Review 5.  Targeted cancer therapy: promise and reality.

Authors:  Shoshana Klein; Alexander Levitzki
Journal:  Adv Cancer Res       Date:  2007       Impact factor: 6.242

Review 6.  The kinase inhibitor imatinib--an immunosuppressive drug?

Authors:  D Wolf; H Tilg; H Rumpold; G Gastl; A M Wolf
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

7.  Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.

Authors:  David Wisniewski; Caryl L Lambek; Chongyuan Liu; Annabel Strife; Darren R Veach; Bhushan Nagar; Matthew A Young; Thomas Schindler; William G Bornmann; Joseph R Bertino; John Kuriyan; Bayard Clarkson
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

8.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

Authors:  Bhushan Nagar; William G Bornmann; Patricia Pellicena; Thomas Schindler; Darren R Veach; W Todd Miller; Bayard Clarkson; John Kuriyan
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

Review 9.  BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.

Authors:  Charles A Schiffer
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

Review 10.  Therapy options in imatinib failures.

Authors:  Pablo Ramirez; John F DiPersio
Journal:  Oncologist       Date:  2008-04
View more
  4 in total

1.  IMAGEtags: Quantifying mRNA Transcription in Real Time with Multiaptamer Reporters.

Authors:  J Ray; I Shin; M Ilgu; L Bendickson; V Gupta; G A Kraus; M Nilsen-Hamilton
Journal:  Methods Enzymol       Date:  2016-04-13       Impact factor: 1.600

2.  Light-up and FRET aptamer reporters; evaluating their applications for imaging transcription in eukaryotic cells.

Authors:  Muslum Ilgu; Judhajeet Ray; Lee Bendickson; Tianjiao Wang; Ivan M Geraskin; George A Kraus; Marit Nilsen-Hamilton
Journal:  Methods       Date:  2015-12-17       Impact factor: 3.608

3.  Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.

Authors:  Sameer Nikhar; Ioannis Siokas; Lisa Schlicher; Seungheon Lee; Mads Gyrd-Hansen; Alexei Degterev; Gregory D Cuny
Journal:  Eur J Med Chem       Date:  2021-02-03       Impact factor: 6.514

4.  Live-cell imaging of Pol II promoter activity to monitor gene expression with RNA IMAGEtag reporters.

Authors:  Ilchung Shin; Judhajeet Ray; Vinayak Gupta; Muslum Ilgu; Jonathan Beasley; Lee Bendickson; Samir Mehanovic; George A Kraus; Marit Nilsen-Hamilton
Journal:  Nucleic Acids Res       Date:  2014-04-20       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.